

1 **Supplement:** Seroprevalence with cut off obtained from literature for different (combinations of) antibodies against Ebola
 2 virus antigens as measured by the Luminex or FANG ELISA in Health care providers from Boende, DRC.

	Antigen	Cutoff	Positives	Seroprevalence	Age /year	M vs F	Direct Contact with patients: Direct vs indirect	Working Hospital vs elsewhere	Experienced Ebola outbreak/patients vs others
			n (N)	% (95% conf. Int.)	p-value	p-value	(p-value)	(p-value)	p-value
FANG ELISA	GP-EBOV-m	607 EU/ml	49 (694)	7	0.73	0.35	0.24	0.67	0.61
	GP-EBOV-m	381 MFI/100 beads	104 (698)	14	0.005	0.22	0.05	0.81	0.24
	GP-EBOV-k	501 MFI/100 beads	89 (698)	13	0.02	0.81	0.05	0.99	0.45
	VP40-EBOV-m	580 MFI/100 beads	69 (698)	10	0.14	0.11	0.41	0.35	0.16
Luminex	NP-EBOV-m	950 MFI/100 beads	8 (698)	1	0.54	0.57	0.31	0.16	0.08
	GP-EBOV-m+NP-EBOV-m	C1	0 (698)	0					
	GP-EBOV-m+VP40-EBOV-m	C2	19 (698)	3	0.92	0.37	0.91	0.38	0.13
	NP-EBOV-m+VP40-EBOV-m	C3	2 (698)	0.2					
Luminex and FANG ELISA	GP-EBOV-m	C4	6 (694)	0.8					

3 *cutoff (C) represent values obtained from literature and previous studies

4 C1= 381 MFI/100 beads for GP-EBOV-m and 580MFI/100 beads for NP-EBOV-m

5 C2=381 MFI/100 beads for GP-EBOV-m and 950 MFI/100 beads for VP40-EBOV-m

6 C3= 950 MFI/100 beads for NP-EBOV-m and 580 MFI/100 beads for VP40-EBOV-m

7 C4= 607 EU/ml and 381MFI/100beads for GP-EBOV-k and GP-EBOV-m